Floatz logo

VARENICLINE

Nicotine Dependence

University of California, San DiegoSmall moleculePhase 4 / ApprovedActive
A
81/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
71/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Nicotine Dependence cohort.

Asset / SponsorPhaseRating
Nicotine
Brown University
Phase 4A
Semaglutide
University of Oklahoma
Phase 4BBB
Naltrexone
Yale University
Phase 4BBB
Minocycline
University of Maryland, Baltimore
Phase 4BB
Cephalexin
Mayo Clinic
Phase 4BB

View all 26 →

Same molecule, other indications

VARENICLINE is also rated in:

schizoaffective disorderActive
BB
Indicative · Phase 4
68 / 100
View asset →
schizophreniaActive
BB
Indicative · Phase 4
66 / 100
View asset →
schizophreniform disorderDormant
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →